These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30957173)

  • 1. Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations.
    Lee WS; Singh G
    Lab Med; 2019 Oct; 50(4):381-389. PubMed ID: 30957173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas.
    Singh G
    Lab Med; 2019 Apr; 50(2):189-193. PubMed ID: 30423164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas.
    Singh G; Xu H
    Lab Med; 2021 Jul; 52(4):390-398. PubMed ID: 33180138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies:  High False-Positive Rate.
    Singh G
    Am J Clin Pathol; 2016 Aug; 146(2):207-14. PubMed ID: 27473738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.
    Singh G
    J Clin Med Res; 2017 Jan; 9(1):46-57. PubMed ID: 27924175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays.
    Katzmann JA; Dispenzieri A; Kyle RA; Snyder MR; Plevak MF; Larson DR; Abraham RS; Lust JA; Melton LJ; Rajkumar SV
    Mayo Clin Proc; 2006 Dec; 81(12):1575-8. PubMed ID: 17165636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum free light chains in clinical laboratory diagnostics.
    Jenner E
    Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Free Immunoglobulin Light Chains in Urine.
    Singh G; Cotter T; Ye Mon M; Xu H; Bollag RJ
    J Appl Lab Med; 2023 Nov; 8(6):1101-1114. PubMed ID: 37725944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
    Singh G
    J Appl Lab Med; 2020 Nov; 5(6):1358-1371. PubMed ID: 33150391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical considerations for the measurement of free light chains in serum.
    Tate JR; Gill D; Cobcroft R; Hickman PE
    Clin Chem; 2003 Aug; 49(8):1252-7. PubMed ID: 12881439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POEMS Syndrome with IgG-λ/IgA-κ Biclonal Gammopathy and Abnormal Serum Free Light Chain Ratio: a Case Report.
    Ham JY; Suh JS; Lee WK; Song KE
    Ann Clin Lab Sci; 2015; 45(6):702-6. PubMed ID: 26663802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease.
    Singh G; Arinze N; Manthei DM; Plapp FV; Bollag RJ
    Lab Med; 2023 Sep; 54(5):527-533. PubMed ID: 36857478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
    Singh G; Bollag R
    Lab Med; 2020 Nov; 51(6):592-600. PubMed ID: 32285117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
    Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods].
    Schneider N; Wynckel A; Kolb B; Sablon E; Gillery P; Maquart FX
    Ann Biol Clin (Paris); 2013; 71(1):13-9. PubMed ID: 23396425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.